Clinical trials: insulin glargine
Diabetes Mellitus, Type 1
A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine
A 3 month, randomized, open label, multi-center study of Technosphere/Insulin compared to insulin aspart in subjects with type 1 diabetes mellitus receiving insulin glargine
- Trial name
- NCT00539396
- Testing
- Technosphere Insulin
- Volunteers
- 110 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus Type 2, Hospitalization
Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes.
Type 2 diabetes (T2D) is a common pathology in hospitalized patients and is associated with multiple comorbidities. Moreover, it is widely known that glycemic excursions increase hospital stay, infections, morbidity and…
- Trial name
- NCT06607224
- Testing
- Experimental (Decision making guided by CGM)
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Type 2 Diabetes Mellitus
Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)
The purpose of the study is to determine whether in patients with early type 2 diabetes,a short-term intensive metabolic intervention comprising of sitagliptin, metformin, basal insulin glargine and lifestyle approaches will be…
- Trial name
- NCT02623998
- Testing
- insulin glargine, sitagliptin/metformin, lifestyle therapy
- Where
- 6 sites in Canada
- Volunteers
- 102 people
- Sponsor
- Population Health Research Institute
Diabetes Mellitus, Type 1
Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes
A study to test for non-inferiority of preprandial HIIP [also known as AIR® Inhaled Insulin Powder][AIR® is a registered trademark of Alkermes,Inc.] compared with preprandial injectable insulin (insulin lispro) with respect to…
- Trial name
- NCT00356109
- Testing
- Human Insulin Inhalation Powder, Injectable insulin, Insulin Glargine
- Where
- 37 sites in United States, Argentina and 7 more
- Volunteers
- 494 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)
The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin glargine as basal insulin therapy in adults with type 2 diabetes.
- Trial name
- IOPE (NCT00510952)
- Testing
- Insulin Lispro Protamine Suspension, Insulin Glargine
- Where
- 17 sites in United States, Brazil and 2 more
- Volunteers
- 471 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy
Primary Objective: To compare the efficacy of insulin glargine (U300) and Lantus in terms of change of glycated hemoglobin A1c (HbA1c) from baseline to endpoint (scheduled at Month 6, Week 26) in patients with type 2 diabetes…
- Trial name
- EDITION AP (NCT02855684)
- Testing
- Insulin glargine (U300), Insulin glargine, Non-insulin antihyperglycemic drugs
- Where
- 54 sites in China, South Korea and 1 more
- Volunteers
- 604 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus
Primary Objective: To compare the 24-hour glycemic profile in continuous glucose monitoring (CGM) between a new formulation of insulin glargine and Lantus at steady state Secondary Objectives: To compare the change of Fasting…
- Trial name
- NCT01676233
- Testing
- insulin glargine (HOE901), insulin glargine- new formulation (HOE901)
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood…
- Trial name
- NCT00097084
- Testing
- insulin detemir, insulin glargine, insulin aspart
- Where
- 60 sites in United States, Finland and 3 more
- Volunteers
- 324 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Study of LY900014 in Participants With Type 1 Diabetes
The main purpose of this study is to evaluate the efficacy of the study drug LY900014 compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in adults with type 1 diabetes (T1D).
- Trial name
- PRONTO-T1D (NCT03214367)
- Testing
- LY900014, Insulin Lispro, Insulin Glargine
- Where
- 172 sites in United States, Argentina and 18 more
- Volunteers
- 1,392 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.
- Trial name
- AWARD-CHN3 (NCT04591626)
- Testing
- Dulaglutide, Insulin Glargine
- Where
- 27 sites in China
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Maturity-Onset Diabetes of the Young
Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes
Maturity-onset diabetes of youth (MODY) are the most frequent monogenic diabetes with autosomic dominant inheritance (2% of diabetes).
- Trial name
- MODY2 (NCT02556840)
- Testing
- insulin therapy
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetes Mellitus, Type 2
Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus
This phase IV study is a prospective open-label multi-center study to investigate the effect of a temporary individualized poly-pharmaceutical De-escalation treatment with the target to regenerate ß-cell function over 12 weeks on…
- Trial name
- NCT04027023
- Testing
- Diabetes mellitus Type 2 De-escalation treatment (DET)
- Where
- 2 sites in United States, Germany
- Volunteers
- 9 people
- Sponsor
- Sciema UG
Diabetes Mellitus, Type 2
DOMME Dose Optimization Multicentric Mexican Evaluation
To evaluate the efficiency of Lantus plus combined oral hypoglycaemic agents in terms of respondents percentage. The respondent is defined as the person achieving a value in the final determination of HbA1c < 7% as its absolute…
- Trial name
- DOMME (NCT00488527)
- Testing
- Insulin glargine
- Where
- Mexico
- Volunteers
- 371 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy
Primary Objective: To investigate the efficacy(HbA1c) at 6 months after adding basal insulin therapy (insulin glargine) to dipeptidyl peptidase-IV (DPP-IV) and metformin plus or minus sulphonylurea Secondary Objectives: 1.
- Trial name
- TED (NCT02027753)
- Testing
- INSULIN GLARGINE, Metformin, DPP-4 inhibitor
- Where
- South Korea
- Volunteers
- 109 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, and North America. The aim of this clinical trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2…
- Trial name
- BEGIN™ (NCT01068678)
- Testing
- insulin degludec, insulin glargine
- Where
- 99 sites in United States, Canada and 6 more
- Volunteers
- 460 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Health Care for Type 1 Diabetes in Developing World
This study is a pilot 2-armed, randomized, open label, clinical trial evaluating the effectiveness of a basal approach to diabetes management as compared to the current standard treatment (regular/NPH).
- Trial name
- NCT01424046
- Testing
- basal insulin glargine, standard therapy
- Where
- Rwanda
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Leukemia, Lymphoma
Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)
The goal of this clinical research study is to learn if intense management and control of blood sugar levels during treatment for acute lymphocytic leukemia, Burkitts lymphoma, or lymphoblastic lymphoma will result in decreased…
- Trial name
- NCT00500240
- Testing
- Insulin Glargine, Insulin Aspart
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Diabetes Mellitus
An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice
The objective of this survey on this registered product is to confirm the efficacy, and safety profile of Lantus in every day medical practice.
- Trial name
- NCT00576368
- Testing
- INSULIN GLARGINE
- Where
- Belgium
- Volunteers
- 4,464 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine by demonstrating change in glycosylated hemoglobin (HbA1c).
- Trial name
- NCT03529123
- Testing
- INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010), INSULIN GLARGINE (HOE901), Metformin
- Where
- 13 sites in India
- Volunteers
- 247 people
- Sponsor
- Sanofi
Diabetes
ADA Linagliptin in Long Term Care
This is a study to determine whether glycemic control, as measured by change in HbA1c and frequency of hypoglycemia, is different between treatment with linagliptin (Tradjenta®) and basal insulin in long term care residents(LTC)…
- Trial name
- NCT02061969
- Testing
- linagliptin, insulin glargine
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- Emory University